SCHEMBL5114417

SCHEMBL5114417

CCN(CCOc1ccc(NC(=O)COc2ccc(C(F)(F)F)cc2Cl)cc1Cl)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
GPR119 Q8TDV5 3/20 0.40
APOBEC3A P31941 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
GPR55 Q9Y2T6 2/20 0.40
TGFBR1 P36897 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 2/20 0.39
EPHX2 P34913 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
HPGD P15428 1/20 0.39
GPR35 Q9HC97 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4163881 0.90 APOBEC3A (0.40) APOBEC3AAPOBEC3GMAPTMEN1KMT2A
SCHEMBL4015006 0.85 MEN1 (0.42) APOBEC3AAPOBEC3GMAPTMEN1KMT2A
SCHEMBL5108941 0.84 RXFP1 (0.56) RXFP1GPR119MAPTMEN1KMT2A
SCHEMBL4010353 0.80 KDR (0.52) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4008897 0.79 KMT2A (0.47) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4010419 0.78 KDM4E (0.49) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4008917 0.77 KDR (0.48) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4006855 0.76 HTR2A (0.47) APOBEC3AAPOBEC3GMAPTMEN1KMT2A
SCHEMBL14209953 0.75 SCN9A (0.44) RXFP1APOBEC3AAPOBEC3GMAPTMEN1
SCHEMBL4014278 0.75 MRGPRX4 (0.47) MAPTMEN1KMT2ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351719-B2 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-04-01 US disclosed
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds MCHR2, MCHR1, NPY1R NR3C1 1309/4885RXFP1 42/4885GPR119 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.